iSpecimen Inc 8-K, filed May 29, 2026
iSpecimen Inc. (ISPC)
About this 8-K
iSpecimen Inc filed this 8-K on May 29, 2026.
Items reported
- Item 5.07: Shareholder vote results
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of Incorporation) |
(Commission File Number) | (IRS Employer Identification No.) |
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including
area code: (
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.07. Submission of Matters to a Vote of Security Holders.
At the reconvened 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of iSpecimen Inc. (the “Company”) on May 29, 2026, of the Company’s 8,478,579 shares of common stock issued and outstanding and eligible to vote as of the record date of November 3, 2025, a quorum of 2,979,059 shares, or approximately 35.14% of the eligible shares, was present or represented by proxy. Each of the matters set forth below is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on November 21, 2025 (the “Proxy Statement”). The following actions were taken at the Annual Meeting:
Proposal No. 1: Election of One Class I Director
The first proposal was the election of one (1) Class I director to serve for a three-year term that expires at the 2028 Annual Meeting of Stockholders, or until the election and qualification of their respective successor in office, subject to their earlier death, resignation or removal. The vote on the proposal was as follows:
| Name of Nominee | FOR | WITHHELD | BROKER NON-VOTE | |||
| Arphing (Tommy) Lee | 562,361 | 150,431 | 2,266,267 |
The nominee was elected.
Proposal No. 2: Ratification of Appointment of Independent Registered Public Accounting Firm
The second proposal was the ratification of the appointment of Bush & Associates CPA LLC as the Company’s independent registered public accounting firm for the year ending December 31, 2025. The vote on the proposal was as follows:
| FOR | AGAINST | ABSTAIN | |||
| 2,424,420 | 155,256 | 399,383 |
Proposal No. 2 was approved by a majority of the votes cast.
Proposal No. 3: Approval of the iSpecimen Inc. 2025 Stock Incentive Plan
The third proposal was the approval of the iSpecimen Inc. 2025 Stock Incentive Plan. The vote on the proposal was as follows:
| FOR | AGAINST | ABSTAIN | BROKER NON-VOTE | |||
| 461,073 | 186,740 | 64,979 | 2,266,267 |
Proposal No. 3 was approved by a majority of the votes cast.
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: May 29, 2026
| iSPECIMEN INC. | |||
| By: | /s/ Katharyn Field | ||
| Name: | Katharyn Field | ||
| Title: | Chief Executive Officer | ||
2